Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
9(69%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
8
62%
Ph phase_3
2
15%
Ph phase_1
3
23%

Phase Distribution

3

Early Stage

8

Mid Stage

2

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
3(23.1%)
Phase 2Efficacy & side effects
8(61.5%)
Phase 3Large-scale testing
2(15.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

9

trials recruiting

Total Trials

13

all time

Status Distribution
Active(12)
Completed(1)

Detailed Status

Active, not recruiting6
Recruiting3
Not yet recruiting3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
9
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (23.1%)
Phase 28 (61.5%)
Phase 32 (15.4%)

Trials by Status

active_not_recruiting646%
recruiting323%
not_yet_recruiting323%
completed18%

Recent Activity

9 active trials
Showing 5 of 13
completedphase_2

A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

NCT05918107
active_not_recruitingphase_3

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

NCT06616532
not_yet_recruitingphase_2

PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT07133750
active_not_recruitingphase_2

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC

NCT05756972
active_not_recruitingphase_2

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

NCT05844150
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT05918107Phase 2

A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

Completed
NCT06616532Phase 3

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Active Not Recruiting
NCT07133750Phase 2

PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Not Yet Recruiting
NCT05756972Phase 2

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC

Active Not Recruiting
NCT05844150Phase 2

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Active Not Recruiting
NCT05864105Phase 2

PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma

Active Not Recruiting
NCT06419621Phase 3

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting
NCT05918133Phase 1

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Active Not Recruiting
NCT06837948Phase 2

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

Not Yet Recruiting
NCT05879055Phase 2

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Recruiting
NCT05879068Phase 2

A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC

Active Not Recruiting
NCT06584071Phase 1

A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

Not Yet Recruiting
NCT05918445Phase 1

PM8002 in the Treatment of Patients With Advanced Solid Tumors

Recruiting

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13